...
首页> 外文期刊>Catheterization and cardiovascular interventions: Official journal of the Society for Cardiac Angiography & Interventions >Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis.
【24h】

Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis.

机译:糖尿病和肾硬化患者的严重动脉粥样硬化性肾小动脉狭窄的支架血管成形术。

获取原文
获取原文并翻译 | 示例
           

摘要

Atherosclerotic renal artery stenosis (ARAS) may lead to deterioration of renal function or hypertension. The clinical outcome after stent angioplasty of ARAS on renal function and blood pressure control in patients with diabetes and nephrosclerosis is the subject of some controversy. We have analyzed the results of our single-center experience with stent angioplasty for severe (>/= 70%) ostial ARAS and present here the results of a subgroup analysis of those patients who had diabetes mellitus and nephrosclerosis. From 1996 to 2001, 241 patients underwent stent angioplasty for the treatment of ARAS at our center. Of these, 99 patients had diabetes mellitus (41%) and 176 patients (73%) had nephrosclerosis defined as intrarenal resistance index (RI) >/= 0.7 diagnosed by duplex ultrasound. All lesions (n = 355) were treated successfully. Mean blood pressure at baseline was comparable and significantly improved immediately after the intervention in all groups (nondiabetics: 102 +/- 12 to 93 +/- 10 mm Hg; diabetics: 102 +/- 14 to 93 +/- 11 mm Hg; RI < 0.7: 105 +/- 13 to 95 +/- 10 mm Hg; RI = 0.7-0.8: 100 +/- 12 to 92 +/- 10 mm Hg; RI > 0.8: 102 +/- 15 to 92 +/- 11 mm Hg; P < 0.0001 each). Baseline serum creatinine was not significantly lower in nondiabetics compared to diabetics (1.46 +/- 0.9 vs. 1.62 +/- 1.2 mg %; P < 0.05) and increased in patients with nephrosclerosis (RI < 0.7: 1.18 +/- 0.6 mg %; RI = 0.7-0.8: 1.57 +/- 1.1 mg %; RI > 0.8: 1.96 +/- 1.6 mg %). Except for patients without nephrosclerosis who had a normal baseline creatinine, serum creatinine decreased significantly in all subgroups during follow-up. Stent angioplasty of ARAS offers favorable acute and long-term clinical results for the preservation of the renal function and for blood pressure control in patients with diabetes mellitus and nephrosclerosis. Cathet Cardiovasc Intervent 2003;58:510-515.
机译:动脉粥样硬化性肾动脉狭窄(ARAS)可能导致肾功能恶化或高血压。 ARAS支架血管成形术对糖尿病和肾硬化患者肾功能和血压控制的临床结果是一些争议的主题。我们分析了单中心治疗严重(> / = 70%)口腔ARAS的单中心经验的结果,并在此介绍了患有糖尿病和肾硬化的患者的亚组分析结果。从1996年到2001年,在我们中心有241例患者接受了支架血管成形术治疗ARAS。其中,有99例糖尿病患者(41%)和176例患者(73%)患有肾硬化,其定义为经双重超声诊断的肾内抵抗指数(RI)> / = 0.7。所有病变(n = 355)均已成功治疗。干预后所有组的基线平均血压均具有可比性,并且显着改善(非糖尿病患者:102 +/- 12至93 +/- 10 mm Hg;糖尿病患者:102 +/- 14至93 +/- 11 mm Hg; RI <0.7:105 +/- 13至95 +/- 10毫米汞柱; RI = 0.7-0.8:100 +/- 12至92 +/- 10毫米汞柱; RI> ​​0.8:102 +/- 15至92 + /-11毫米汞柱;每个P <0.0001)。与糖尿病患者相比,非糖尿病患者的血清血清肌酐没有显着降低(1.46 +/- 0.9与1.62 +/- 1.2 mg%; P <0.05),而肾硬化患者则升高(RI <0.7:1.18 +/- 0.6 mg% ; RI = 0.7-0.8:1.57 +/- 1.1mg%; RI> 0.8:1.96 +/- 1.6mg%。除基线肌酐正常的无肾硬化患者外,所有亚组的血清肌酐在随访期间均显着下降。 ARAS支架血管成形术为糖尿病和肾硬化患者的肾功能保持和血压控制提供了良好的急性和长期临床效果。 Cathet Cardiovasc Intervent 2003; 58:510-515。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号